JTE-162
Phase 1Small molecule
JTE-162 is one of 9 small molecule programs targeting Cryopyrin-Associated Periodic Syndrome. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Cryopyrin-Associated Periodic Syndrome
#DrugCompanyPhaseTrials
1ACZ885
NovartisPhase 3
ATI-450
AAclaris Therapeutics, Inc.
Phase 2
Tranilast
NNuon Therapeutics, Inc.
Phase 2
Ilaris
NovartisPreclinical
VTX2735
ZZomagen Biosciences Ltd.
Phase 2
Arcalyst
KKiniksa Pharmaceuticals (UK), Ltd.
Preclinical
Kineret
SSwedish Orphan Biovitrum
Preclinical
JTE-162
AAkros Pharma Inc.
Phase 1
ARCALYST
RegeneronPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for JTE-162. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- AAkros Pharma Inc.